Skip to main content
Top
Published in: Supportive Care in Cancer 10/2007

01-10-2007 | Original Article

Nail changes due to docetaxel—a neglected side effect and nuisance for the patient

Authors: Dorte Winther, Ditte Marie Saunte, Marianne Knap, Vera Haahr, Anders Bonde Jensen

Published in: Supportive Care in Cancer | Issue 10/2007

Login to get access

Abstract

Goals of work

The objective of this study is to estimate the frequency and severity of nail changes due to treatment with the cytotoxic drug docetaxel and, secondly, to estimate how the nail changes effects the patients cosmetically and functionally in their daily activities. Finally, we want to clarify whether fungal infection could contribute in causing the nail changes.

Materials and methods

Fifty-five patients with metastatic breast cancer in treatment with the cytotoxic drug docetaxel participated in the study. They filled out two questionnaires about their experience with possible nail changes. The frequency of fungal infection was examined. At each of the two visits, information about the number of treatment cycles, dose of docetaxel the patient received, frequency of lymph oedema, previous treatment with chemotherapy and the reason of discontinuance of treatment, if relevant, were registered. Finally, photos were taken to document the nail changes in hands and feet.

Main results

Fifty-eight percent had some degree of nail changes and an increase to 88.5% was seen after three additional cycles. A large proportion of the patients experienced the nail changes as a cosmetic nuisance, and more than 32% had functional problems.

Conclusion

Nail changes occur more frequently than previous studies have shown. Furthermore, our study indicates that the nail changes are affecting a large proportion of the patients, both cosmetically and functionally, which may lead to a decrease in their quality of life. No significant association was found according to the possible relation between nail changes and fungal infection.
Literature
1.
go back to reference National Board of Health (2004) Cancer incidence in Denmark, 2000. National Board of Health, Denmark National Board of Health (2004) Cancer incidence in Denmark, 2000. National Board of Health, Denmark
2.
go back to reference Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F, Polonia J (1999) Nail changes secondary to docetaxel (taxotere). Dermatology 198(3):288–290PubMedCrossRef Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F, Polonia J (1999) Nail changes secondary to docetaxel (taxotere). Dermatology 198(3):288–290PubMedCrossRef
3.
4.
go back to reference Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ (1999) Effect of onychomycosis on quality of life. J Am Acad Dermatol 38(5):702–704CrossRef Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ (1999) Effect of onychomycosis on quality of life. J Am Acad Dermatol 38(5):702–704CrossRef
5.
go back to reference Howard A, Nicolopoulos J (2002) Docetaxel-induced nail dystrophy. Australas J Dermatol 43(4):293–296PubMedCrossRef Howard A, Nicolopoulos J (2002) Docetaxel-induced nail dystrophy. Australas J Dermatol 43(4):293–296PubMedCrossRef
6.
go back to reference Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS (2000) Onycholysis as a complication of systemic chemotherapy. Cancer 88(10):2367–2371PubMedCrossRef Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS (2000) Onycholysis as a complication of systemic chemotherapy. Cancer 88(10):2367–2371PubMedCrossRef
7.
go back to reference Markman M (2003) Managing taxane toxicities. Support Care Cancer 11:144–147PubMed Markman M (2003) Managing taxane toxicities. Support Care Cancer 11:144–147PubMed
8.
go back to reference Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F (2003) Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 14:333–337PubMedCrossRef Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F (2003) Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 14:333–337PubMedCrossRef
9.
go back to reference Nilsson J, Svejgaard EL (2004) Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 47:131–135PubMedCrossRef Nilsson J, Svejgaard EL (2004) Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 47:131–135PubMedCrossRef
10.
go back to reference Obermair A, Binder M, Barrada M, Bancher-Todesca D, Asseryanis E, Kubista E (1998) Onycholysis in patients treated with docetaxel. Ann Oncol 9(2):230–231PubMedCrossRef Obermair A, Binder M, Barrada M, Bancher-Todesca D, Asseryanis E, Kubista E (1998) Onycholysis in patients treated with docetaxel. Ann Oncol 9(2):230–231PubMedCrossRef
11.
go back to reference Patten SF, Jacob C (1998) Nail bed dyschromia secondary to docetaxel therapy. Arch Dermatol 134:1167–1168PubMedCrossRef Patten SF, Jacob C (1998) Nail bed dyschromia secondary to docetaxel therapy. Arch Dermatol 134:1167–1168PubMedCrossRef
12.
go back to reference Robinet G, Thomas P, Perol M, Vergnenegre A, Lena H, Taytard A, Paillotin D, Bessa EH, Schuller-Lebeau MP (2000) Phase 2 study of docetaxel in inoperable advanced non-small cell lung cancer. Bull Cancer 87(3):253–258PubMed Robinet G, Thomas P, Perol M, Vergnenegre A, Lena H, Taytard A, Paillotin D, Bessa EH, Schuller-Lebeau MP (2000) Phase 2 study of docetaxel in inoperable advanced non-small cell lung cancer. Bull Cancer 87(3):253–258PubMed
13.
go back to reference Saarinen A, Jekunen A, Halme M, Pyrhonen S, Tamminen K, Boyer Roubille N, Mattson K (1996) A phase 2 trial of docetaxel in advanced non-small cell lung cancer. Anticancer Drugs 7(8):890–892PubMedCrossRef Saarinen A, Jekunen A, Halme M, Pyrhonen S, Tamminen K, Boyer Roubille N, Mattson K (1996) A phase 2 trial of docetaxel in advanced non-small cell lung cancer. Anticancer Drugs 7(8):890–892PubMedCrossRef
14.
go back to reference Scotté F, Taurani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23(19):4424–4429PubMedCrossRef Scotté F, Taurani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23(19):4424–4429PubMedCrossRef
15.
go back to reference Stanton AW, Modi S, Mellor RH, Peters AM, Svensson WE, Levick JR, Mortimer PS (2006) A quantitative lymphoscintigraphic evaluation of lymphatic function in the swollen hands of women with lymphoedema following breast cancer treatment. Clin Sci (Lond) 110(5):553–561CrossRef Stanton AW, Modi S, Mellor RH, Peters AM, Svensson WE, Levick JR, Mortimer PS (2006) A quantitative lymphoscintigraphic evaluation of lymphatic function in the swollen hands of women with lymphoedema following breast cancer treatment. Clin Sci (Lond) 110(5):553–561CrossRef
16.
go back to reference ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alakl M (1994) A phase 2 trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 5(6):527–532PubMed ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alakl M (1994) A phase 2 trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 5(6):527–532PubMed
17.
go back to reference Vanhooteghem O, Richert B, Vindevoghel A, Vandenbossche L, Vandeveire A, De La Brassinne M (2000) Subungual abcess. A new ungual side-effect related to docetaxel therapy. Br J Dermatol 143:462–464PubMedCrossRef Vanhooteghem O, Richert B, Vindevoghel A, Vandenbossche L, Vandeveire A, De La Brassinne M (2000) Subungual abcess. A new ungual side-effect related to docetaxel therapy. Br J Dermatol 143:462–464PubMedCrossRef
18.
go back to reference Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R (2002) Docetaxel-induced nail changes—a neurogenic mechanism. J Neurooncol 58:167–174PubMedCrossRef Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R (2002) Docetaxel-induced nail changes—a neurogenic mechanism. J Neurooncol 58:167–174PubMedCrossRef
19.
go back to reference Wiseman LR, Figgitt DP (2000) Docetaxel: an update of its use in advanced breast cancer. Drugs 59(3):621–651PubMedCrossRef Wiseman LR, Figgitt DP (2000) Docetaxel: an update of its use in advanced breast cancer. Drugs 59(3):621–651PubMedCrossRef
Metadata
Title
Nail changes due to docetaxel—a neglected side effect and nuisance for the patient
Authors
Dorte Winther
Ditte Marie Saunte
Marianne Knap
Vera Haahr
Anders Bonde Jensen
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0232-0

Other articles of this Issue 10/2007

Supportive Care in Cancer 10/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine